Taysha Gene Therapies Acquires Exclusive Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program, Now Known as TSHA-120, for the Treatment of Giant Axonal Neuropathy, a Rare and Severe Neurodegenerative Disease
Program invented in the lab of Dr. Steven Gray, Taysha's Chief Scientific Advisor, immediately transforms Taysha into a sustainable pivotal-stage gene therapy company
Clinical and preclinical data package validates the scientific approach of Dr. Steven Gray, UT Southwestern, and Taysha, with readthrough to existing portfolio
Groundbreaking clinical trial run by the NIH is the first intrathecally dosed gene therapy program in history
Human proof-of-concept data for TSHA-120 demonstrated clear arrest of disease progression and long-term durability at therapeutic dose levels in patients with giant axonal neuropathy
Plans to engage with regulatory agencies in the United States, Europe and J
